Phio Pharmaceuticals (PHIO) Net Margin (2012 - 2019)
Phio Pharmaceuticals' (PHIO) quarterly Net Margin came in at 10219.05% in Q1 2019, down 48427.0% on a YoY basis from N/an in Q1 2018, and down 290.14% quarter-over-quarter from 2619.3% in Q3 2018.
Analysis
Phio Pharmaceuticals (PHIO) Net Margin (2012 - 2019) Analysis & Trends
Phio Pharmaceuticals (PHIO) has reported Net Margin for 8 consecutive years, with 10219.05% the latest figure, recorded in Q1 2019.
- For the quarter ending Q1 2019, Net Margin fell 48427.0% year-over-year to 10219.05%; the trailing twelve-month figure through Dec 2019 stood at 42795.24% (down 3746190.0% YoY), and the FY2019 full-year result was 42419.05%, down 3708571.0% from the prior year.
- Net Margin retreated to 10219.05% in Q1 2019 per PHIO's latest filing, from 2619.3% in the prior quarter.
- Across five years, Net Margin topped out at 2619.3% in Q3 2018 and bottomed at 24577.78% in Q2 2016.
- Historically, Net Margin has averaged 11911.38% across 5 years, with a median of 9976.92% in 2018.
- The sharpest annual moves came in 2015 and 2016: Net Margin surged 472170 bps in 2015, then slumped 1310412 bps in 2016.
- Over 5 years, Net Margin stood at 9205.88% in 2015, then slumped by 167 bps to 24577.78% in 2016, then jumped by 46 bps to 13346.67% in 2017, then soared by 80 bps to 2619.3% in 2018, then slumped by 290 bps to 10219.05% in 2019.
- According to Business Quant data, Net Margin over the past three periods registered 10219.05%, 2619.3%, and 3277.59% for Q1 2019, Q3 2018, and Q2 2018 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -20,152.98% |
| 10 | Phio Pharmaceuticals | 12.08 Mn | 12.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2019 | -10,219.05% |
| Sep 30, 2018 | -2,619.30% |
| Jun 30, 2018 | -3,277.59% |
| Mar 31, 2018 | -9,734.78% |
| Dec 31, 2017 | -13,346.67% |
| Jun 30, 2016 | -24,577.78% |
| Mar 31, 2016 | -22,310.00% |
| Mar 31, 2015 | -9,205.88% |
| Dec 31, 2014 | -19,757.14% |
| Sep 30, 2014 | -18,162.50% |
| Jun 30, 2014 | -26,825.00% |
| Mar 31, 2014 | -13,927.59% |
| Dec 31, 2013 | -12,844.83% |
| Sep 30, 2013 | -3,810.87% |
| Jun 30, 2013 | -1,937.78% |
| Mar 31, 2013 | -33,856.60% |
| Dec 31, 2012 | -6,575.00% |
| Sep 30, 2012 | -5,124.56% |